DexCom Inc. (NASDAQ:DXCM) reported $1.26 billion in Q4 2025 revenue, exceeding Wall Street expectations and marking a 13% YoY growth. Gross margins also improved to 63.5%. Full-year revenue reached $4.662 billion, surpassing guidance. CEO Jake Leach highlighted product advancements and market expansions, reiterating 2026 revenue guidance of $5.16-$5.25 billion.

DexCom Inc. (DXCM) designs, manufactures, and sells continuous glucose monitoring (CGM) systems for people with diabetes, including the Dexcom G6 and G7 CGM devices. The company’s products provide real-time glucose readings through wearable sensors, transmitting data to smartphones or insulin delivery systems. Management emphasized growth fueled by products like the G7 and Stelo.

CEO Jake Leach highlighted DexCom’s strong performance in 2025, emphasizing expanded access to CGM systems and the launch of the DexCom G7 15 Day System. Looking ahead, management reiterated 2026 revenue guidance of $5.16-$5.25 billion, citing category expansion, Stelo’s contribution, and new features. DexCom is positioned for continued growth and market expansion.

While DexCom (DXCM) shows investment potential, some AI stocks may offer higher upside and less downside risk. Investors seeking undervalued AI stocks can explore opportunities beyond DexCom. For those interested in AI investments, consider exploring other options beyond DexCom to maximize potential returns and mitigate risks.

Read more at Yahoo Finance: DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook